

In the claims:

Please amend the claims as follows:

1. **(Original)** A targeted oligonucleotide construct comprising: a targeting moiety which localizes to a site in an organism; an oligonucleotide complementary to a nucleic acid of interest; and a detectable label.
2. **(Original)** A targeted oligonucleotide construct as in claim 1, wherein the targeting moiety is selected from a lipid, an antibody, a lectin, a ligand, a sugar, a steroid, a hormone, a nutrient, and a protein.
3. **(Original)** A targeted oligonucleotide construct as in claim 1, wherein the detectable label is selected from a chemiluminescent label, a radioisotope, a fluorescent label, a paramagnetic contrast agent, and a metal chelate.
4. **(Currently Amended)** A targeted oligonucleotide construct as in claim 1, wherein the oligonucleotide is ~~selected from an antisense oligonucleotide and or~~ an antisense oligonucleotide analog that is modified to enhance its efficacy, pharmacokinetic properties, or physical properties.
5. **(Currently Amended)** A targeted oligonucleotide construct as in claim 1, wherein the detectable label and the targeting moiety are coupled to the oligonucleotide in any configuration that maintains the desired activity of said label and said moiety.
6. **(Currently Amended)** A targeted oligonucleotide construct as in claim 1, wherein the oligonucleotide and the detectable label are coupled to the targeting moiety in any configuration that maintains the desired activity of said label and said moiety.
7. **(Currently Amended)** A targeted oligonucleotide construct as in claim 1, wherein the targeting moiety and the oligonucleotide are coupled to the detectable label in any configuration that maintains the desired activity of said label and said moiety.
8. **(Original)** A targeted oligonucleotide conjugate comprising: a targeting moiety which localizes to a site in an organism; an oligonucleotide complementary to a nucleic acid of interest, and a therapeutic agent.

9. **(Original)** A targeted oligonucleotide construct as in claim 8, wherein the targeting moiety is selected from a lipid, an antibody, a lectin, a ligand, a sugar, a steroid, a hormone, a nutrient, and a protein.
10. **(Original)** A targeted oligonucleotide construct as in claim 8, wherein the therapeutic agent is selected from an enzyme, an enzyme inhibitor, a receptor ligand, a radioisotope, an antibiotic, a steroid, a hormone, a polypeptide, a glycopeptide, a phospholipid, and a drug.
11. **(Currently Amended)** A targeted oligonucleotide construct as in claim 8, wherein the oligonucleotide is ~~selected from an antisense oligonucleotide and or~~ an antisense oligonucleotide analog that is modified to enhance its efficacy, pharmacokinetic properties, or physical properties.
12. **(Currently Amended)** A targeted oligonucleotide construct as in claim 8, wherein the therapeutic agent and the targeting moiety are coupled to the oligonucleotide in any configuration that maintains the desired activity of said label and said moiety.
13. **(Currently Amended)** A targeted oligonucleotide construct as in claim 8, wherein the oligonucleotide and the therapeutic agent are coupled to the targeting moiety in any configuration that maintains the desired activity of said label and said moiety.
14. **(Currently Amended)** A targeted oligonucleotide construct as in claim 8, wherein the targeting moiety and the oligonucleotide are coupled to the therapeutic agent in any configuration that maintains the desired activity of said label and said moiety.

Claims 15-24 (Cancelled)

25. A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide analog that is selected from the group consisting of: an antisense oligonucleotide that is modified with a cell uptake facilitating moiety, an antisense oligonucleotide that is modified with a stabilizing moiety, an antisense oligonucleotide that is modified to enhance its solubility, and an antisense oligonucleotide that is modified to enhance its resistance to nuclease digestion.

26. **(New)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide analog derivatized with a moiety selected from the group consisting of: biotin, amino glycoside, lipophilic, phosphorothioate, morpholino and deoxy.
27. **(New)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide analog derivatized with a phosphorothioate moiety.
28. **(New)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is specific to mRNA.
29. **(New)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is specific to a gene selected from the group consisting of : C-myb, N-myc, C-myc and PSA gene specific antisense.
30. **(New)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide analog that is selected from the group consisting of: an antisense oligonucleotide that is modified with a cell uptake facilitating moiety, an antisense oligonucleotide that is modified with a stabilizing moiety, an antisense oligonucleotide that is modified to enhance its solubility, and an antisense oligonucleotide that is modified to enhance its resistance to nuclease digestion.
31. **(New)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide analog derivatized with a moiety selected from the group consisting of: biotin, amino glycoside, lipophilic, phosphorothioate, morpholino and deoxy.
32. **(New)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide analog derivatized with a phosphorothioate group.
33. **(New)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide

analog that is specific to a gene selected from the group consisting of : C-myb, N-myc, C-myc and PSA gene specific antisense.

34. **(New)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is specific to mRNA.